NUDT1

Oxidized purine nucleoside triphosphate hydrolase

43,360 patent compounds predicted against NUDT1, 20,515 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL100370	0.46	8/20
SCHEMBL264853	0.49	7/20
SCHEMBL100468	0.46	7/20
SCHEMBL100939	0.46	7/20
SCHEMBL98273	0.44	7/20
SCHEMBL98619	0.43	7/20
SCHEMBL45713	0.56	6/20
SCHEMBL218367	0.51	6/20
SCHEMBL250475	0.51	6/20
SCHEMBL101422	0.48	6/20
SCHEMBL306661	0.47	6/20
SCHEMBL397466	0.47	6/20
SCHEMBL414100	0.47	6/20
SCHEMBL99235	0.42	6/20
SCHEMBL99352	0.42	6/20
SCHEMBL100067	0.41	6/20
SCHEMBL100052	0.40	6/20
SCHEMBL215756	0.70	5/20
SCHEMBL29154	0.69	5/20
SCHEMBL102315	0.57	5/20

Germline variants in NUDT1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full NUDT1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to NUDT1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis	PHASE3	COMPLETED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
Targeting de Novo Pyrimidine Biosynthesis by Leflunomide for the Treatment of COVID-19 Virus Disease	PHASE3	COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia	PHASE1/PHASE2	COMPLETED
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial	PHASE1/PHASE2	COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity	PHASE2	COMPLETED
Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine	PHASE2	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Nucleoside Therapy in Patients With Telomere Biology Disorders	PHASE1	RECRUITING
A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients	EARLY_PHASE1	RECRUITING
Functional Pharmacogenomics of Childhood Acute Lymphoblastic Leukemia in Taiwan	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia	nan	COMPLETED
A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer	nan	UNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
DNA Adductomics for Colorectal Cancer Investigation	nan	UNKNOWN
Dietary Interventions Evaluating Transport of Uric Acid Across the Tubules	nan	COMPLETED
Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19	nan	UNKNOWN
Mechanistic Studies of Teriflunomide in RRMS	nan	COMPLETED
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders	nan	RECRUITING
In Vivo Assessment of Histamine Pharmacodynamics	nan	WITHDRAWN
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)	nan	UNKNOWN
Pre-genotype NUDT 15 R139C on Reducing Thiopurine-induced Leucopenia in Inflammatory Bowel Disease	nan	UNKNOWN
Predicting Response to Capecitabine in Women With Metastatic Breast Cancer	nan	COMPLETED
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart	nan	UNKNOWN
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis	nan	UNKNOWN
Epidemiology of Gout in French Polynesia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NUDT1 binder may also engage these)

Protein	Name	Similarity
Q7ZWC3	—	0.998	Q7ZWC3 →
F1P963	—	0.995	F1P963 →
P53369	—	0.994	P53369 →
P53368	—	0.994	P53368 →
P95781	—	0.976	P95781 →
B5XNX5	—	0.976	B5XNX5 →
P56380	—	0.975	P56380 →
A7ZP69	—	0.975	A7ZP69 →
Q0T2N2	—	0.975	Q0T2N2 →
B4TPH8	—	0.975	B4TPH8 →
B7NN72	—	0.975	B7NN72 →
P59659	—	0.974	P59659 →
P41354	—	0.974	P41354 →
B7N5L6	—	0.974	B7N5L6 →
Q8Z544	—	0.974	Q8Z544 →
B5BCQ0	—	0.974	B5BCQ0 →
Q5PC77	—	0.974	Q5PC77 →
B7MXT2	—	0.974	B7MXT2 →
B6I7J4	—	0.974	B6I7J4 →
B7M5T3	—	0.974	B7M5T3 →
Q83KB9	—	0.974	Q83KB9 →
P44932	—	0.973	P44932 →
B7LM80	—	0.973	B7LM80 →
A4WDK7	—	0.973	A4WDK7 →
A9N5B7	—	0.973	A9N5B7 →
A1ADA3	—	0.973	A1ADA3 →
B7MG18	—	0.973	B7MG18 →
B4SYW7	—	0.972	B4SYW7 →
Q5LWT6	—	0.972	Q5LWT6 →
Q8FFM5	—	0.972	Q8FFM5 →